Literature DB >> 36224375

Lifestyle intervention in obese pregnancy and cardiac remodelling in 3-year olds: children of the UPBEAT RCT.

Paul D Taylor1, Haotian Gu2, Hannah Saunders3, Federico Fiori4, Kathryn V Dalrymple3, Priyanka Sethupathi3, Liana Yamanouchi3, Faith Miller3, Bethany Jones3, Matias C Vieira3, Claire Singh3, Annette Briley3, Paul T Seed3, Dharmintra Pasupathy3,5, Paramala J Santosh4, Alan M Groves6, Manish D Sinha3,2,7, Philip J Chowienczyk2, Lucilla Poston3.   

Abstract

BACKGROUND/
OBJECTIVES: Obesity in pregnancy has been associated with increased childhood cardiometabolic risk and reduced life expectancy. The UK UPBEAT multicentre randomised control trial was a lifestyle intervention of diet and physical activity in pregnant women with obesity. We hypothesised that the 3-year-old children of women with obesity would have heightened cardiovascular risk compared to children of normal BMI women, and that the UPBEAT intervention would mitigate this risk. SUBJECTS/
METHODS: Children were recruited from one UPBEAT trial centre. Cardiovascular measures included blood pressure, echocardiographic assessment of cardiac function and dimensions, carotid intima-media thickness and heart rate variability (HRV) by electrocardiogram.
RESULTS: Compared to offspring of normal BMI women (n = 51), children of women with obesity from the trial standard care arm (n = 39) had evidence of cardiac remodelling including increased interventricular septum (IVS; mean difference 0.04 cm; 95% CI: 0.018 to 0.067), posterior wall (PW; 0.03 cm; 0.006 to 0.062) and relative wall thicknesses (RWT; 0.03 cm; 0.01 to 0.05) following adjustment. Randomisation of women with obesity to the intervention arm (n = 31) prevented this cardiac remodelling (intervention effect; mean difference IVS -0.03 cm (-0.05 to -0.008); PW -0.03 cm (-0.05 to -0.01); RWT -0.02 cm (-0.04 to -0.005)). Children of women with obesity (standard care arm) compared to women of normal BMI also had elevated minimum heart rate (7 bpm; 1.41 to 13.34) evidence of early diastolic dysfunction (e prime) and increased sympathetic nerve activity index by HRV analysis.
CONCLUSIONS: Maternal obesity was associated with left ventricular concentric remodelling in 3-year-old offspring. Absence of remodelling following the maternal intervention infers in utero origins of cardiac remodelling. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: The UPBEAT trial is registered with Current Controlled Trials, ISRCTN89971375.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36224375     DOI: 10.1038/s41366-022-01210-3

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.551


  45 in total

1.  Maternal obesity and risk of cardiovascular diseases in offspring: a population-based cohort and sibling-controlled study.

Authors:  Neda Razaz; Eduardo Villamor; Giulia M Muraca; Anna-Karin Edstedt Bonamy; Sven Cnattingius
Journal:  Lancet Diabetes Endocrinol       Date:  2020-07       Impact factor: 32.069

Review 2.  Identifying 'at risk' women and the impact of maternal obesity on National Health Service maternity services.

Authors:  Nicola Heslehurst
Journal:  Proc Nutr Soc       Date:  2011-08-22       Impact factor: 6.297

Review 3.  Influence of maternal obesity on the long-term health of offspring.

Authors:  Keith M Godfrey; Rebecca M Reynolds; Susan L Prescott; Moffat Nyirenda; Vincent W V Jaddoe; Johan G Eriksson; Birit F P Broekman
Journal:  Lancet Diabetes Endocrinol       Date:  2016-10-12       Impact factor: 32.069

4.  Maternal obesity and gestational diabetes: Impact on arterial wall layer thickness and stiffness in early childhood - RADIEL study six-year follow-up.

Authors:  Johnny K M Sundholm; Linda Litwin; Kristiina Rönö; Saila B Koivusalo; Johan G Eriksson; Taisto Sarkola
Journal:  Atherosclerosis       Date:  2019-02-12       Impact factor: 5.162

5.  Evidence for sympathetic origins of hypertension in juvenile offspring of obese rats.

Authors:  Anne-Maj Samuelsson; Abigail Morris; Natalia Igosheva; Shona L Kirk; Joaquim M C Pombo; Clive W Coen; Lucilla Poston; Paul D Taylor
Journal:  Hypertension       Date:  2009-11-09       Impact factor: 10.190

6.  Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of developmental programming.

Authors:  Anne-Maj Samuelsson; Phillippa A Matthews; Marco Argenton; Michael R Christie; Josie M McConnell; Eugene H J M Jansen; Aldert H Piersma; Susan E Ozanne; Denise Fernandez Twinn; Claude Remacle; Anthea Rowlerson; Lucilla Poston; Paul D Taylor
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

7.  Influence of maternal obesity on the association between common pregnancy complications and risk of childhood obesity: an individual participant data meta-analysis.

Authors:  Bernadeta Patro Golab; Susana Santos; Ellis Voerman; Debbie A Lawlor; Vincent W V Jaddoe; Romy Gaillard
Journal:  Lancet Child Adolesc Health       Date:  2018-09-07

Review 8.  Preconceptional and maternal obesity: epidemiology and health consequences.

Authors:  Lucilla Poston; Rishi Caleyachetty; Sven Cnattingius; Camila Corvalán; Ricardo Uauy; Sharron Herring; Matthew W Gillman
Journal:  Lancet Diabetes Endocrinol       Date:  2016-10-12       Impact factor: 32.069

9.  The programming of cardiac hypertrophy in the offspring by maternal obesity is associated with hyperinsulinemia, AKT, ERK, and mTOR activation.

Authors:  Denise S Fernandez-Twinn; Heather L Blackmore; Lee Siggens; Dino A Giussani; Christine M Cross; Roger Foo; Susan E Ozanne
Journal:  Endocrinology       Date:  2012-10-15       Impact factor: 4.736

10.  Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years.

Authors:  Rebecca M Reynolds; Keith M Allan; Edwin A Raja; Sohinee Bhattacharya; Geraldine McNeill; Philip C Hannaford; Nadeem Sarwar; Amanda J Lee; Siladitya Bhattacharya; Jane E Norman
Journal:  BMJ       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.